- Universal Ibogaine (IBO) is pleased to announce the appointment of Dr. Ian Rabb as Chief Clinics Officer
- Dr. Rabb is one of the most recognized and respected leaders in Addiction Treatment in Canada
- Caroline Egan sat down with Dr. Rabb to discuss the opportunity
- Universal Ibogaine is a life sciences company researching medicalized ibogaine-centred addiction care
- Universal Ibogaine Inc. (IBO) is unchanged, trading at C$0.23 per share at 11 am ET
Universal Ibogaine (IBO) is pleased to announce the appointment of addiction treatment and clinic operations veteran Dr. Ian Rabb as Chief Clinics Officer.
Dr. Ian Rabb is one of the most recognized and respected leaders in Addiction Treatment in Canada. A certified Interventionist and addictions specialist, Dr. Rabb has helped thousands of people overcome addiction.
Caroline Egan sat down with Dr. Rabb to discuss the opportunity to guide Universal Ibogaine’s mission to research and deliver medicalized ibogaine-centred addiction care.
In his own words, Dr. Rabb says,
“In my 20 years in the addiction recovery business I have not seen anything that has the power of Ibogaine to disrupt the devastating effects of addiction and help change the course of peoples lives who have been living with addiction. The opportunity to join the leadership of Universal Ibogaine, to guide in their mission to advance the science of addiction treatment to a level we have never seen before provided an opportunity to be of service that I could not refuse. I am so grateful for the opportunity to lead the clinic operations and development area of Universal Ibogaine.”
Universal Ibogaine is a life sciences company with a mission to research and deliver medicalized ibogaine-centred addiction care.
Universal Ibogaine Inc. (IBO) is unchanged, trading at C$0.23 per share at 11 am ET.
